FRONTIER Clinical Trial

Study at a Glance

Estimated Time Commitment

9 Months

Eligibility

18 years to 101 years

Diagnosis Required

Type 2 diabetes with kidney disease

Diseases Being Studied

Diabetic Kidney Diseases
Location: Texas Diabetes Institute

The FRONTIER clinical trial is phase 2 study evaluating the efficacy, safety and immunogenicity of new medication in adults with diabetic kidney disease who are already on standard of care therapy including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and dapagliflozin, and still have protein in the urine. The total duration of study participation is 9 months.

Location: Texas Diabetes Institute

Meet Your Clinical Research Team

Contact us

Principal Investigator: Dr. Shweta Bansal; Sponsor: AstraZeneca

PI: Dr. Shweta Bansal; Sponsor: AstraZeneca